麗珠集團(000513.SZ)：擬向麗珠微球公司增資2.09億元
格隆匯 8 月 25日丨麗珠集團(000513.SZ)公佈，此次擬變更募集資金投資項目“長效微球技術研發平台建設項目”之實施主體。公司“長效微球技術研發平台建設項目”計劃投資金額為4.11億元，主要投資建設內容包括臨牀前研究、臨牀研究、購買儀器設備、微球車間建設及植入劑車間建設等，其實施主體為麗珠集團及下屬全資子公司麗珠集團麗珠製藥廠(“麗珠製藥廠”)。截至2020年6月30日，本項目已使用募集資金投入2.47億元。
此次擬將“長效微球技術研發平台建設項目”實施主體由麗珠集團及麗珠製藥廠變更為麗珠集團及麗珠微球公司，此次變更後，“微球車間建設”和“植入劑車間建設”子項目將由麗珠微球公司實施。有關此次變更暨向全資子公司增資的詳細安排如下：
公司使用自有資金以貨幣方式向麗珠微球公司增資人民幣2.09億元，麗珠製藥廠以其擁有的微球製劑相關生產性資產(包含其使用募集資金形成的固定資產)並經合資格評估機構予以評估作價向麗珠微球公司增資1.39億元，雙方共計向麗珠微球公司增資3.48億元。此次增資完成後，麗珠微球公司註冊資本將變更為人民幣35,348.685萬元。
此次增資完成後，“長效微球技術研發平台建設項目”子項目“微球製劑車間”和“植入劑車間”將由麗珠微球公司實施，並負責完成上述項目尚未完工部分的建設,同時，除上述認繳出資資產外，麗珠製藥廠在實施上述車間建設項目過程中使用募集資金形成的、此次未作為出資資產的其他資產，未來將以公允價格轉讓給麗珠微球公司，以保證上述項目的順利實施。另外，本公司將對長效緩釋微球製劑業務的組織架構、平台合作及人員配置等進行調整，依託麗珠集團研發條件及麗珠微球公司即將擁有的相關生產車間優勢，確保在研項目的順利實施，積極開展新的研發項目立項，“長效微球技術研發平台建設項目”將由麗珠集團及麗珠微球公司共同實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
